Physician profile
Hani Badi
NPI 1619317054
$5,625.96
in general payments reported to CMS, 2019-2025
36 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $713 · 2021: $812 · 2022: $685 · 2023: $871 · 2024: $921 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $603.34 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $529.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $468.56 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Baxter Healthcare | $452.87 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $423.63 | 2021-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $382.01 | 2020-2025 | Terlivaz, Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.54 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Merck Sharp & Dohme LLC | $327.38 | 2019-2025 | Zerbaxa, Recarbrio, Winrevair |
| Actelion Pharmaceuticals US, INC. | $293.00 | 2019-2024 | Uptravi, Opsumit |
| Insmed, INC. | $200.74 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $175.46 | 2019-2021 | |
| Genzyme Corporation | $168.76 | 2019-2025 | |
| Philips North America LLC | $149.97 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $126.97 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $120.45 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $117.31 | 2019-2024 | Xarelto |
| Pfizer INC. | $97.13 | 2024-2025 | |
| Mylan Specialty L.P. | $71.90 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $66.75 | 2021-2024 | Glassia |
| Advanced Respiratory, INC | $63.59 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $61.52 | 2022-2025 | Zevtera, Xacduro, Giapreza |
| Viatris Specialty LLC | $53.55 | 2025 | Yupelri |
| Phadia US INC. | $50.32 | 2023-2024 | Immunocap |
| Gilead Sciences, INC. | $38.57 | 2023 | Veklury |
| Electromed, INC. | $30.18 | 2022 | |
| Verona Pharma, INC. | $25.85 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $25.58 | 2025 | Purified Cortrophin Gel |
| Inogen, INC. | $24.92 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $22.02 | 2021 | |
| Medivance, INC. | $19.58 | 2021 | |
| Amgen INC. | $18.94 | 2024 | Tezspire |
| Inspire Medical Systems, INC. | $17.79 | 2023 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $13.93 | 2019 | |
| Pulmonx Corporation | $13.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.74 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Badi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.